Cartesian Therapeutics (RNAC) investor relations material

Executive summary

• Net loss for Q1 2026 was $39.2 million, up from $17.7 million in Q1 2025, driven by higher R&D expenses and a significant increase in the fair value of the contingent value right (CVR) liability.

• Revenue decreased 93% year-over-year to $0.1 million, reflecting lower grant revenue and no collaboration/license revenue in Q1 2026.

• Cash, cash equivalents, and restricted cash totaled $120.4 million as of March 31, 2026, expected to fund operations into mid-2027.

• The company continues to advance its lead cell therapy candidate, Descartes-08, in Phase 3 for myasthenia gravis, Phase 2 for myositis, and Phase 1/2 for pediatric autoimmune diseases.

• Descartes-08 has received multiple FDA designations, including Orphan Drug and Rare Pediatric Disease for various indications.

Financial highlights

• Total revenue for Q1 2026 was $0.1 million, down from $1.1 million in Q1 2025.

• Research and development expenses increased 33% year-over-year to $19.5 million, mainly due to the ongoing Phase 3 AURORA trial for Descartes-08 in MG.

• General and administrative expenses decreased to $7.1 million from $8.3 million year-over-year, primarily from lower professional and consulting fees.

• Net cash used in operating activities was $22.1 million, slightly lower than $23.1 million in Q1 2025.

• $14.6 million was raised in Q1 2026 through an at-the-market equity offering.

Outlook and guidance

• Management expects continued operating losses and increased expenses as clinical programs advance.

• Existing cash resources are projected to fund operations into mid-2027, including completion of the Phase 3 AURORA trial.

• Additional capital will be sought through equity, debt, or strategic collaborations as needed.

• Near-term milestones are anticipated across the clinical pipeline.